A risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications was recently approved by the Food and Drug Administration (FDA) to ensure the benefits of these opioid analgesics outweigh the risks. The REMS supports national efforts to address the prescription drug abuse epidemic.
As part of the strategy, all ER/LA opioid analgesic companies must provide education for prescribers of these medications. The requirement led to development of the Collaborative on REMS Education (CORE), a multidisciplinary group of 10 partners and three organizations. CORE has designed an educational curriculum with shared tools, resources, and outcomes to meet the requirements of the FDA REMS Blueprint.
These educational activities help ensure all physicians have the knowledge and skills they need to prescribe extended-release, long-acting opioid medications safely and effectively.
As a result of this CORE initiative, physicians have free access to 2013-14 ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care, available for 3 AMA PRA Category 1 Credits™. Physicians can take advantage of this program until Dec. 31.
Action, June 2, 2014